Eywa aims to make mark in US market with own label, skip generic trend

The company, which is backed by Eight Roads Ventures, has got approval for 20 of its 36 products in the US and the EU

Eight Roads Ventures-backed Eywa Pharma, founded by two former Mylan employees, is looking at expanding to the US and European Union (EU) markets with a portfolio of limited competition products. It plans to have a front-end marketing presence in the US. 

Targeting 16 products in the US market by the end of this year, Eywa Pharma wants to have its own label in the world's largest single-country pharma market, unlike most of its Indian peers who dabble in the generic space. 

The company has a total of 36 products filed for approval between the US and Europe. It has an approval for